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Insight into partial agonism by observing multiple
equilibria for ligand-bound and Gs-mimetic
nanobody-bound β1-adrenergic receptor
Andras S. Solt1, Mark J. Bostock 1, Binesh Shrestha2, Prashant Kumar1, Tony Warne3,
Christopher G. Tate 3 & Daniel Nietlispach 1
A complex conformational energy landscape determines G-protein-coupled receptor (GPCR)
signalling via intracellular binding partners (IBPs), e.g., Gs and β-arrestin. Using 13C methyl
methionine NMR for the β1-adrenergic receptor, we identify ligand efﬁcacy-dependent
equilibria between an inactive and pre-active state and, in complex with Gs-mimetic nano-
body, between more and less active ternary complexes. Formation of a basal activity complex
through ligand-free nanobody–receptor interaction reveals structural differences on the
cytoplasmic receptor side compared to the full agonist-bound nanobody-coupled form,
suggesting that ligand-induced variations in G-protein interaction underpin partial agonism.
Signiﬁcant differences in receptor dynamics are observed ranging from rigid nanobody-
coupled states to extensive μs-to-ms timescale dynamics when bound to a full agonist. We
suggest that the mobility of the full agonist-bound form primes the GPCR to couple to IBPs.
On formation of the ternary complex, ligand efﬁcacy determines the quality of the interaction
between the rigidiﬁed receptor and an IBP and consequently the signalling level.
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G-protein-coupled receptors (GPCRs) relay an extracellularstimulus across the plasma membrane, activating cellularsignalling pathways via coupling to intracellular binding
partners (IBP) such as heterotrimeric G-proteins and β-arrestins.
GPCRs control a wide range of physiological processes and are
implicated in many disease states1. Rhodopsin-like GPCRs are
estimated to be targeted by ~30% of current drugs2. β-adrenergic
receptors (βAR) are essential in the sympathetic nervous system;
β1AR is the predominant subtype in the heart, and is targeted by
drugs such as β-blockers in the context of heart failure3. βARs
show constitutive (basal) activity, with β1 at a lower but never-
theless signiﬁcant level, compared to β2AR4, 5.
Over 170 crystal structures have been solved of nearly 40 unique
receptors6, 7 in the presence of different ligands and IBPs8–10,
substantially developing our understanding of how these receptors
function. NMR studies indicate a complex, dynamic conforma-
tional energy landscape consisting of several states in equili-
brium11–20, with substantial variations for different receptors.
Allosteric coupling networks are observed17 along with correlations
of ligand structure and efﬁcacy with spectral parameters12, 17.
GPCRs are known to show varying degrees of constitutive
activity21, with sampling by the receptor in the absence of a ligand
(apo form) of activated states observed in ﬂuorescence22 and
NMR studies18. Addition of ligands shifts this equilibrium either
towards the inactive form (inverse agonists) or towards activated
conformations (agonists), which can couple to multiple intracel-
lular signalling pathways18, 23.
Crystallisation of a receptor in the fully active state requires the
presence of a cytoplasmic signalling partner. A range of native
binding partners and mimetics (Gs, nanobodies, β-arrestins,
mini-Gs and the transducin α-subunit C-terminal peptide)10 have
been used, and the resulting active structures for the μ-opioid
receptor (μOR)24, adenosine A2A receptor (A2AR)25, β2AR26, 27,
muscarinic acetylcholine receptor M228 and rhodopsin29 are all
very similar pointing towards a uniﬁed mechanism for receptor
activation. The hallmarks of an active state are a large lateral
displacement of the cytoplasmic end of transmembrane helix 6
(TM6) from the helix bundle, accompanied by a characteristic
rearrangement of conserved residues (Arg3.50, Tyr5.58 and Tyr7.53
(superscripts refer to Ballesteros–Weinstein numbering30)) that
seem to stabilise the receptor in its active conformation10. For
agonist-bound A2AR, an intermediate-active state structure is
found in the absence of IBP and there is also spectroscopic evi-
dence for an active-like intermediate19, 31. No such equivalent has
been observed for agonist-bound β1AR, reﬂecting subtle varia-
tions in the conformational energy landscape. However, NMR
studies of β1- and β2AR indicate a ligand efﬁcacy-dependent
equilibrium between inactive and active states11, 12, 17. In addi-
tion, accelerated molecular dynamics (MD) simulations may be
used to assess receptor activation, e.g., following the pathway
from the active (ternary) structure of β2AR to the inactive
receptor, potentially providing evidence for an intermediate
conformation, as well as coupling between the ligand and G-
protein-binding sites32. However, currently for β1AR, there are no
reported active state structures.
Evidence indicates that a range of inactive, intermediate,
active-like and active states are involved in GPCR function, which
likely exist in equilibrium. However, crystallographic studies are
unable to address questions regarding the role of receptor
dynamics accompanying the process of activation, and further
questions remain related to agonist efﬁcacy, partial agonism,
constitutive activity and sampling of active states in the absence
of G-protein.
Here, we use NMR to investigate the conformational diversity
and dynamic nature of coupling between activated receptor states
of turkey β1AR and Gs-mimetic nanobodies. We show that β1AR
in an active ternary complex has differing spectral signatures
when bound to diverse activating ligands that correlate ligand
efﬁcacy, providing structural insight into the mechanism of par-
tial agonism. Structural variations on TM5 and TM6 point to
differences in the receptor–IBP interaction, which we hypothesise
regulates the receptor’s guanine–nucleotide exchange factor
(GEF) activity. Our study also indicates extensive conformational
changes that affect large parts of the receptor during ligand-
independent basal activation. We show that both the ternary
complexes and the nanobody-only bound forms are less dynamic,
while the full agonist-bound receptor in the absence of IBP is at
its most dynamic form, indicating extensive sampling of different
active-like conformational states that are primed to bind a range
of intracellular signalling partners. This emphasises the vital role
of receptor dynamics for coupling to a variety of different sig-
nalling pathways, for biased signalling and for partial agonism.
Results
β1AR constructs and NMR signal assignment. A thermo-
stabilised turkey β1AR33 construct, modiﬁed from the previously
published β44-m23 β1AR34 was functionally expressed in
baculovirus-infected insect cells (Methods). Compared to the
published construct, the level of thermostabilisation was sub-
stantially reduced through reverse mutagenesis of V90M2.53,
A227Y5.58 and L282A (IL3). The ﬁnal β1AR construct (Supple-
mentary Fig. 1) contained R68S1.59, E130W3.41 and F327A7.37 as
the only remaining thermostabilising mutations and C116L3.27
and C358A (CT) for improved expression yields17. Selective 13C
methyl methionine labelling involved supplementing methionine-
deﬁcient SF4 growth media with labelled amino acid. To reduce
overlap in the NMR spectra, the number of methionine residues
was reduced from 12 (including the N-terminus) to seven
through removal of M44L, M48L, M179L, M281A and M338A
creating β1AR-MetΔ5, with methionines M1, M902.53 (TM2),
M153 (IL2), M1784.62 (TM4/EL2), M2235.54 (TM5), M2836.28
(TM6) and M2966.41 (TM6) remaining (Supplementary Fig. 1b).
For some samples, L108M (EL1) and L190M (EL2) were intro-
duced providing additional reporters in extracellular loops 1 and
2. None of these additional methionines altered the thermal
stability of the receptor. A comparison with residues in other class
A GPCRs is shown in Supplementary Table 1. The expressed
receptor was solubilised in lauryl-maltose-neopentyl-glycol
(LMNG) and puriﬁed to 95% homogeneity judged by
SDS–PAGE, using one-step nickel afﬁnity chromatography. The
methyl methionine signals of [13C-methyl-Met] β1AR-MetΔ5
were assigned in 1H, 13C SOFAST heteronuclear multiple quan-
tum coherence (HMQC) spectra using a mutagenesis approach
for a range of different ligand-bound states (Supplementary
Fig. 2). In the case of agonistic ligands, this assignment approach
was extended to the nanobody-bound ternary complexes and to
the ligand-free nanobody-bound receptor form.
Correlations between ligand efﬁcacy and chemical shift. To
examine the effect of ligand binding, 1H, 13C HMQC spectra were
recorded at 308 K for β1AR-MetΔ5 in the apo form and in the
presence of saturating amounts of 7-methylcyanopindolol (very
weak partial agonist)35, carvedilol (weak partial agonist), cyano-
pindolol (weak partial agonist), salbutamol (partial agonist),
isoprenaline (full agonist) and adrenaline (full agonist), respec-
tively (Supplementary Table 2)36. Apo- and ligand-bound spectra
(Supplementary Fig. 3) showed substantial chemical shift changes
for M2235.54 and M2966.41 (TM5, TM6), which correlated with
the ligand efﬁcacy (Fig. 1), suggesting an equilibrium involving
two states exchanging fast relative to the chemical shift difference
between the two signals, known as the NMR timescale
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(Supplementary Note 1). M2235.54 and M2966.41, located in the
cytoplasmic half of the receptor, are sensitive reporters of the
receptor’s activation state. Smaller changes were observed for
M2836.28 and M153 (IL2) emphasising that structural changes
related to ligand binding extend as far as the cytoplasmic side of
the receptor and well beyond the ligand-binding pocket (Fig. 1).
In β1AR, M902.53 is on the extracellular half of TM2 pointing
towards the ligand-binding pocket. M902.53 samples a major and
minor conformation in the unliganded state (M90a and M90b),
indicative of at least two receptor conformations in the apo form
(Fig. 1; Supplementary Fig. 3). Carvedilol-bound receptor showed
two peaks for M902.53 at chemical shifts different from those in
the apo form but close to the M90a state. For the partial agonists
7-methylcyanopindolol, cyanopindol and salbutamol, the major
peak, which also corresponded to the major signal in the apo
state, gradually shifted towards smaller ppm values. Notably,
M902.53 was absent from the isoprenaline-bound spectrum,
suggesting a more dynamic state in complex with a full agonist
(Fig. 1; Supplementary Fig. 3). In addition, two shifts were
observed for M1784.62 (TM4) in all states, consistent with
sampling of at least two conformations by the EL2 region
(Supplementary Fig. 3).
β1AR shows increased dynamics in the agonist-bound state.
Loss of the M902.53 peak from the isoprenaline-bound β1AR
spectra suggested increased signal broadening due to conforma-
tional exchange with rates similar to the NMR timescale (Sup-
plementary Table 3). Short sample lifetimes and low experimental
sensitivity limited the use of NMR spin relaxation tools, although
these have been used for single-site measurements37, while
interpreting signal linewidths was also unreliable (Supplementary
Note 2). Instead, we used relative and normalised peak intensities
as a proxy for detecting varying protein dynamics between
individual receptor forms. Intensity variations were particularly
pronounced for M902.53, M2235.54 and M2966.41. M2235.54 and
M2966.41 are sensitive reporters of the activation state on the
cytoplasmic side of β1AR and for each spectrum, their peak
intensities were expressed as an intensity ratio relative to M153
(IL2) as a reference signal (Supplementary Table 4). Relative peak
intensities for M2235.54 and M2966.41 were determined for two
ligand series of β1AR-MetΔ5 and β1AR-MetΔ5-L190M, respec-
tively (Supplementary Fig. 4). Smaller intensities indicated
increasingly dynamic, exchange-broadened states. Normalised
intensities were obtained by expressing the relative ratios as a
proportion of the maximum peak intensity for a particular resi-
due in a full series of spectra, where ‘1’ represents the least
dynamic state and smaller values indicate increased conforma-
tional ﬂuctuations on the μs-to-ms timescale (Fig. 2). While
relative intensities allowed a direct comparison of M2235.54 and
M2966.41 conformational dynamics, normalised intensities
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Fig. 1 1H, 13C HMQC spectra of ligand-bound methyl 13C-Met β1AR-MetΔ5-L190M show resonance positions that correlate with ligand efﬁcacies. Chemical
shift changes for 2D 1H, 13C HMQC spectra for [13C-methyl-Met] β1AR shown for the apo form (blue) and orthosteric ligands in order of efﬁcacy (h); 7-
methylcyanopindolol (very weak partial agonist, orange), carvedilol (weak partial agonist, red), cyanopindolol (weak partial agonist, green), salbutamol
(partial agonist, purple) and isoprenaline (full agonist, pink). The crystal structure of β1AR (PDB code 4BVN) is shown in b with methionine residues used in
this study shown as red spheres. The various methionines are shown separately; aM90, c M153, eM223, dM283, i M296. The centres of the resonances
are indicated by coloured dots. Correlations between ligand efﬁcacy and a linear combination of the chemical shifts (aδ1H þ bδ13C þ c) are shown in f and g
with M223 ﬁt to 1045:1δ1H  111:0δ13C þ 3839:8 and M296 to 634:1δ1H  239:9δ13C þ 5614:1. Full spectra are shown in Supplementary Fig. 3
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allowed comparison of the overall dynamics between the different
receptor states and constructs. To eliminate bias from the refer-
ence signal, intensity ratios were also determined using the M190
(EL2) peak and the methyl signal of receptor-bound LMNG as
the reference signal. Similar trends were obtained for all three
cases (Supplementary Fig. 5a; Supplementary Table 5).
The full agonist-bound forms with isoprenaline or adrenaline
showed consistently lower relative intensities for residues
M2235.54 and M2966.41 than the partial agonist-bound forms
(salbutamol, cyanopindolol and 7-methylcyanopindolol) or the
apo state. Salbutamol-bound β1AR is more mobile than the other
partial agonist-bound receptors but is still considerably more
rigid than full agonist-bound receptor (Fig. 2). Very similar
trends for the dynamics of the cytoplasmic side of TM5 and TM6
were also found for other mutants of β1AR-MetΔ5 (M178A,
M223L, M283A and M296A) used for the residue-speciﬁc
assignment of the methionine signals (Supplementary Fig. 6;
Supplementary Table 4). The data consistency across a wide range
of mutants and ligands supports the interpretation of signal
intensities in the context of changes in receptor dynamics.
However, other sources that inﬂuence R2 relaxation, e.g.,
variations in dipolar interactions following side chain repacking
could also affect peak heights.
At 308 K, M2235.54 and M2966.41 signals for isoprenaline-bound
β1AR-MetΔ5-L190M were very weak. On lowering the tempera-
ture to 298 K, both signals increased in intensity, and a second
signal for M2235.54 was resolved (Fig. 3), characteristic of
intermediate exchange on the NMR timescale at 308 K, leading
to extensive peak broadening; upon temperature reduction, the
exchange became slow enough to resolve the exchanging states as
individual signals (Supplementary Table 3). Further temperature
reduction to 288 K preserved the more intense main signal
compared to 308 K; however, it became difﬁcult to determine the
total number of signals as some apparent peaks were very close to
the noise level. Both M2235.54 and M2966.41 13C chemical shift
positions shifted towards the apo-receptor peak as the temperature
was decreased (Supplementary Fig. 7; Supplementary Note 3).
Structural and dynamic changes in the ternary complex. To
investigate conformational changes on forming the β1AR ternary
complex, we recorded 1H, 13C HMQC spectra of isoprenaline-
bound β1AR-MetΔ5-L190M after the addition of a stoichiometric
amount of nanobody, using two nanobodies, Nb8026 and
Nb6B938. In the ternary full agonist/receptor/nanobody com-
plexes, both nanobodies are known to have nM-binding afﬁnities
to the receptor38. Substantial changes were observed upon for-
mation of the fully active ternary complex through addition of
Nb6B9 (Fig. 4). Peak positions for residues in the distant extra-
cellular region were affected as well as in the cytoplasmic region
proximal to the nanobody-binding site. The largest chemical shift
changes were observed for M2235.54 and M2966.41 indicating
substantial changes in TM5 and TM6 upon nanobody docking.
Large displacements on the cytoplasmic side were also seen for
M2836.28 (TM6) and M153 (IL2). The changes were much more
substantial than for full agonist binding to the apo form (without
nanobody) (Supplementary Fig. 8). Differences were also detected
on the extracellular side for M1784.62 (TM4/EL2), M1905.21 (EL2)
and M108 (EL1) (Fig. 4). Identical results were obtained for
binding to Nb80 (Supplementary Fig. 2p).
Compared to ligand-only-bound receptor, normalised peak
intensities for M2235.54 and M2966.41 were substantially
increased in the ternary complex, indicating signiﬁcantly more
rigid receptor on the μs-to-ms timescale (Fig. 2). This was
consistently observed for both nanobodies with β1AR-MetΔ5-
L190M as well as for other β1AR-MetΔ5 mutant receptor
constructs (M153A, M178A, M223L, M283A and M296A)
(Supplementary Fig. 6).
Ligand efﬁcacy affects ternary complex chemical shifts. The
structural ﬁngerprint of β1AR ternary complexes was investigated
in the presence of the partial agonist cyanopindolol, agonist sal-
butamol and full agonist adrenaline and the spectral signatures
compared with the isoprenaline-bound ternary complex, using
the higher-afﬁnity nanobody, Nb6B9. Changes were observed in
both the intracellular and extracellular halves of the GPCR, with
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Fig. 2 Normalised peak intensities of M223 and M296 reﬂect differences in dynamics that depend on the receptor state. Normalised peak intensities
comparing residue M223 vs. M296 for the β1AR-MetΔ5 (a) and β1AR-MetΔ5-L190M (b) constructs. Relative intensities (Supplementary Fig. 4) were
determined for each spectrum by calculating the peak intensity relative to the M153 signal. This was converted to a normalised intensity by setting the
maximum intensity in each series to one, where one represents a lack of slow conformational ﬂuctuations that lead to peak broadening and lower values
represent increased µs-to-ms conformational dynamics. The different receptor states are shown as colour-coded circles: ligand bound (orange), apo (blue),
nanobody bound (green) and ternary complex (red). The coloured bars along the top and the right-hand side of each graph indicate the direction of
increasing µs–ms dynamics for residues M223 and M296, respectively. The red area indicates receptor states that are highly dynamic (µs–ms timescale)
and blue indicates less dynamic, more rigid receptor states. Both constructs show a very similar pattern of intensities (dynamics) with full agonist-bound
forms showing the greatest mobility for M223 and M296 and ternary complexes showing the greatest restriction in motion for these residues. Ligand-
bound receptor and the apo form cluster around 0.5–0.6 normalised intensity units indicating some amount of motion (for a discussion of timescales
see Supplementary Notes 1 and 2)
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substantial shifts detected for M1784.62, and M2966.41 and smaller
shifts for M153 (IL2), M2235.54 and M2836.28 (Fig. 5; Supple-
mentary Fig. 9).
Notably, M2966.41 and to a lesser extent M153 (IL2), M1784.62
and M2235.54 showed a correlation between ligand efﬁcacy and
chemical shift positions (Fig. 5). As for nanobody-free receptor,
M1784.62 shows two conformations, with only one showing an
efﬁcacy-dependent shift. While these measurements were done at
308 K, a repeat of the measurement for the salbutamol-bound
β1AR-MetΔ5-L190M ternary complex at 293 K showed a small
shift change for M2235.54 and M2966.41 away from the signal of the
ternary isoprenaline towards smaller ppm (Supplementary Figs. 7,
10). Comparable observations are also made for the cyanopindolol-
and isoprenaline-bound complexes. The shift changes correlating
with ligand efﬁcacy together with the observed temperature
dependence suggested that M2235.54 and M2966.41 existed in
equilibrium between states exchanging faster than the NMR
timescale (Supplementary Table 3). For the salbutamol-bound
ternary complex, the decrease in temperature caused a reduction in
relative peak intensities for M2235.54 and M2966.41 consistent with
fast exchange becoming comparable to the NMR timescale
(Supplementary Table 6).
Ligand-free basal activity complex with a nanobody. In view of
the reported basal activity for βAR5, structural evidence for an
interaction between β1AR and G-protein mimetic nanobody in
the absence of an agonist was sought. The nanobody–β1AR afﬁ-
nity was expected to be lower in the absence of agonists. Using a
15-fold nanobody excess, ligand-free receptor was observed pre-
dominantly as nanobody-bound (based on NMR signal integra-
tion: Nb6B9 99.5% bound; Nb80 96% bound). Substantial
chemical shift changes were observed in the basal complex for
both nanobodies relative to the apo form. Affected positions
included residues at the extracellular side (M190 (EL2), M1784.62)
and at the cytoplasm (M2235.54, M2966.41, M2836.28 and M153
(IL2)) (Fig. 6). Several residues showed slow exchange between
the apo- and nanobody-bound receptor form (Supplementary
Table 3), e.g., M2235.54 and M2966.41, allowing Kd estimation
using peak volumes. NMR titrations for β1AR-MetΔ5 and β1AR-
MetΔ5-L190 in the apo form with Nb80 and Nb6B9 provided Kd
estimates of ca. 56 and 8 μM, respectively, which were several
orders of magnitude weaker than in the presence of
isoprenaline38.
For the receptor bound to Nb80 or Nb6B9, relative signal
intensities for M2235.54 and M2966.41 were smaller than in the
ternary agonist complexes but noticeably larger than in the apo-
or ligand-bound receptor forms (Fig. 2; Supplementary Fig. 4).
Overall peak positions for the basal activity complex appeared
more similar to the ternary complexes than the apo- or
isoprenaline-bound receptor (Supplementary Fig. 11). Further
small shifts on addition of isoprenaline resulted in a spectrum
that was superimposable with the ternary complex formed by
addition of a nanobody to isoprenaline-bound receptor (Supple-
mentary Fig. 12). Isoprenaline addition affected residues
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Fig. 3 Temperature dependence of chemical shifts and signal intensities in
isoprenaline-bound β1AR-MetΔ5-L190M reveal a highly dynamic receptor.
2D 1H, 13C HMQC spectra (a) for the β1AR-MetΔ5-L190M construct
recorded at 288 (blue), 298 (orange) and 308 K (red) showing the
temperature dependence of the spectra. Resonance centres are indicated
by coloured dots. All residues are seen to move with changing temperature,
with substantial shifts for L190M and M1/M283, M223 and M296.
Intensity changes are observed for M223 and M296 and at 298 K, M223
appears in two conformations (M223a and M223b). (Spectra were aligned
using the isopropyl methyl group of unbound isoprenaline as a reference.)
In b intensities, shown as signal-to-noise ratios (SNR), are plotted for M223
vs. M296 with uncorrected values in blue and corrected values accounting
for the temperature and viscosity (η) changes (Supplementary Table 6)
shown in orange. SNRs increase from 308 to 298 K indicating that at 308 K,
M223 and M296 are in intermediate exchange leading to extensive peak
broadening with a shift to slower exchange at lower temperatures, allowing
separate states to be resolved as seen for M223 in a
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Fig. 5 Resonance positions of ternary agonist complexes of β1AR-MetΔ5-L190M with a nanobody correlate with ligand efﬁcacies. 2D 1H, 13C HMQC
spectra for [13C-methyl-Met] β1AR-MetΔ5-L190M or [13C-methyl-Met] β1AR-MetΔ5 bound to Nb6B9 in the apo form (blue) or in a ternary complex with
different orthosteric ligands; cyanopindolol (weak partial agonist, green), salbutamol (partial agonist, purple), isoprenaline (full agonist, pink) and
adrenaline (full agonist, brown), in order of increasing ligand efﬁcacy (k). The full spectrum for the apo form bound to Nb6B9 and full agonist-
(isoprenaline) bound ternary complex is shown in a. Selected regions are also shown to illustrate the changes for residues M296 (b), M178 (c), M223 (f),
M153 (g), M190 (h). Under each spectrum, a linear ﬁt of ligand efﬁcacy to a linear combination of the chemical shifts, aδ1H þ bδ13C þ c, is shown. The
equations determined were as follows: M178 (d), 1510:6δ1H  732:7δ13C þ 9863:4; M296 (e), 5936:4δ1H þ 5:93δ13C þ 11985:7; M223 (i), 1607:4δ1H þ
1258:4δ13C  19056:1 and M153 (j), 11854:9δ1H þ 2691:2δ13C  18476:6. Due to limited sample availability, two β1AR constructs were employed: β1AR-
MetΔ5-L190M was used here with isoprenaline, cyanopindolol and in the apo form, while β1AR-MetΔ5 was used with salbutamol and adrenaline. Except
for the absence of the M190 signal in the spectra of the latter, the two β1AR constructs were identical in terms of stability and binding properties and hence
were used interchangeably
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including M108 (EL1), M178 (EL2) and M190 (EL2) on the
extracellular side of the receptor and M2235.54 and M2966.41 on
the cytoplasmic side. No changes were observed for M2836.28.
Similar observations were made when adding cyanopindolol,
salbutamol or adrenaline to Nb6B9-bound β1AR-MetΔ5.
Increased activation barrier for thermostabilised M90A. To
further assess the inﬂuence of conformational dynamics on
receptor activation, we introduced an additional thermostabilising
mutation, M90A (β1AR-MetΔ5-M90A), known to increase Tm for
the alprenolol-bound (antagonist) β1AR34-324 by +8 °C39. M2966.41
signals for the isoprenaline- and salbutamol-bound states of the
M90A mutant were slightly shifted towards the β1AR-MetΔ5 sig-
nals when bound to lower-efﬁcacy ligands (Fig. 7a). Similar shift
changes were also observed for M2235.54 with β1AR-MetΔ5-M90A
bound to salbutamol. Conversely, signal positions in the corre-
sponding apo form were almost unchanged (Supplementary
Fig. 13). The ligand-only-bound form (salbutamol and isoprena-
line) of M90A gave substantially higher intensity values for
M2235.54 and M2966.41, indicating a more rigid and less exchange-
broadened receptor following the additional thermostabilisation.
The differential increase in relative intensities followed the order
apo< salbutamol< isoprenaline, with little change for the apo
form compared to β1AR-MetΔ5 (Fig. 7b). The relative signal
intensities at 293 and 308 K showed no temperature dependence
for M2966.41 and M2235.54 in the isoprenaline-bound state nor any
ﬁeld dependence (800 vs. 600MHz), supporting a con-
formationally less dynamic, more homogeneous thermostabilised
receptor (Supplementary Table 7a).
Isoprenaline-bound M90A ternary complexes show a similar
overall conformational signature to β1AR-MetΔ5 ternary com-
plexes, with similar relative signal intensities (Fig. 7b; Supple-
mentary Table 7b). However, the M2235.54 and M2966.41 signals
of M90A were slightly shifted towards the partial agonist ternary
complexes of β1AR-MetΔ5 (Fig. 7c).
Discussion
GPCRs require an IBP to populate their fully active state24–29,
characterised by a large translation of the cytoplasmic end of
TM6 compared to the agonist-bound state and the rearrangement
of several key residues believed to stabilise the active state10, 40.
GPCR activation is now understood within a complex con-
formational energy landscape, supported by recent NMR studies
underpinning their highly dynamic nature11–14, 18–20. However,
no active state structure of β1AR currently exists, and many
questions remain surrounding the detailed mechanism of acti-
vation, e.g., how partial agonism manifests through G-protein
interaction.
Using 13C methyl methionine NMR, we investigated a mini-
mally thermostabilised turkey β1AR receptor. We studied apo-
and ligand-bound states and their interaction with G-protein
mimetic nanobodies (Nb80 and Nb6B9), assessing the dynamic
nature of the receptor using a normalised intensity ratio for
residues M2235.54 and M2966.41, which are located on the cyto-
plasmic side of TM5 and TM6 (Supplementary Note 2).
Ligand-bound β1AR spectra show considerable shift changes
for residues near the ligand-binding pocket, e.g., M902.53 and on
the cytoplasmic side of the receptor, e.g., M153 (IL2), M2235.54,
M2836.28 and M2966.41 (Fig. 1; Supplementary Fig. 3). M902.53
shows multiple signals, with the major peak progressing to lower
ppm values as ligand efﬁcacy increases, comparable to M822.53 in
β2AR (M90a, Fig. 1)12. However, M822.53 in β2AR12 shows a
more correlated response to ligands that alter the population of
the two states seen in the apo form and a third conformation
observed in the presence of a full agonist12, 13. In contrast,
M902.53 shows two conformations (M90a and M90c) for 7-
methylcyanopindolol- and cyanopindolol-bound receptor, while
apo receptor shows a different minor conformation, M90b, and
carvedilol-bound receptor a second peak close to the M90a
position. The salbutamol-bound form likely represents a state
sampling more of the active conformation. No clear change in
populations is seen with ligand efﬁcacy. Although M822.53 is
observed in formoterol-bound (full agonist) β2AR, other signals,
e.g., M2155.54 (M2235.54 in β1AR) are missing, indicating
increased motion in the full agonist-bound state consistent with
signal loss in the isoprenaline-bound form of β1AR12. MD
simulations for β2AR suggest that sterically unhindered exchange
between different methyl side chain rotamer environments takes
place on the ns timescale13, too fast to cause the observed mul-
tiple peaks and broadening, suggesting that the vicinity of the
ligand-binding pocket in β1AR is in equilibrium between multiple
slowly exchanging states with a substantial increase in inter-
mediate exchange for isoprenaline-bound receptor.
M2235.54 and M2966.41 undergo large chemical shift changes
correlating with ligand efﬁcacy, indicating a conformational
equilibrium in fast exchange (Supplementary Table 3) between
the inactive state (I), unable to bind a G-protein, and the pre-
active state (A), a more dynamic conformation with increased
accessibility on the cytoplasmic side, populated in the full agonist-
bound receptor (Fig. 1; Supplementary Note 3). The low basal
activity of β1AR indicates that the apo form is almost entirely in
the inactive state (I) with the cytoplasmic half of the receptor in
the closed conformation. Spectral changes for M153 (IL2) and
M2836.28, although smaller, are further evidence of orthosteric
long-range effects that extend as far as the cytoplasmic face of the
receptor.
Correlation with ligand efﬁcacy was observed in a backbone
valine 15N NMR study of tsβ1AR for Val 2265.57, although no
strong correlation was observed for residues in TM6 (Val 2806.25
and Val 2986.43)17, possibly reﬂecting the increased sensitivity of
side chain chemical shifts towards changes in conformational
packing or the higher thermostabilisation of tsβ1AR which
increases conformational rigidity. Notably, ligand-dependent
changes in TM6 were observed in β2AR via the equivalent
Met2796.41 reporter12.
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Comparing normalised signal intensities for M2235.54 and
M2966.41 shows that the full agonist-bound receptor signals are
considerably weaker (~20% maximum intensity) than the other
ligand-bound states and the apo form (~50% maximum inten-
sity), indicating substantial broadening of the (A) state by μs-to-
ms timescale exchange, with adrenaline-bound β1AR appearing
even more dynamic than isoprenaline (Fig. 2; Supplementary
Fig. 4). Lowering the temperature increases the intensity of these
broad isoprenaline-bound receptor signals dramatically (Fig. 3a,
b; Supplementary Fig. 7), suggesting a second, slower exchange
process in the pre-active (A) state which is comparable to the
NMR timescale, indicating sampling of multiple conformations
by the (A) state. At 298 K, M2235.54 appears as two resolved
signals, indicating several conformations in slow exchange
(Supplementary Table 3).
Overall, our data suggest that the pre-active state (A) is highly
mobile on a μs-to-ms timescale, both near the ligand-binding
pocket and on the cytoplasmic side of the receptor. This indicates
that the cytoplasmic side samples at least two, and possibly more
active-like states (A =A′, A′′, A′′′…) in intermediate exchange on
the NMR timescale at 308 K, leading to strong signal broadening.
These states may couple to different IBPs, in which case the
ability of the receptor to access different conformations in the
pre-active state plays an important role in engaging different
downstream-signalling pathways. When bound to lower-efﬁcacy
ligands or in the apo form, β1AR remains conformationally
dynamic, however, less than in the full agonist-bound state. As
the I⇌A equilibrium is shifted towards the more rigid (I) state,
the receptor is conformationally less mobile as revealed by our
intensity data (Fig. 2). A change in the lifetime of the (A =A′, A′′,
A′′′…) states in the presence of different ligands is of course also
possible.
Nanobodies, developed as a Gαs protein mimic26, were shown
to interact with β1AR41, emulating the effect of Gαs-protein on
the receptor and stabilising its active state. Isoprenaline-bound
Nb80- or Nb6B9-β1AR-MetΔ5-L190M ternary complexes show
dramatic spectral changes in the methionine region relative to
isoprenaline-bound receptor (Fig. 4). The largest chemical shift
changes are observed for M2235.54 and M2966.41, consistent with
substantial structural rearrangements in TM5 and TM6 upon
opening of the cytoplasmic half, as shown in β2AR crystal
structures in complex with Nb6B9 or full G-protein26, 27.
Methionine 13Cε chemical shifts report on χ3 dihedral angles,
indicating that for ligand-bound and apo states of β1AR, M2966.41
is in the trans conformation and M2235.54 shows trans/gauche
exchange, shifting towards gauche on increased ligand efﬁcacy,
consistent with increased dynamics in the full agonist-bound
form and the rotamer orientations in β2AR crystal structures
(Supplementary Table 8). β2AR crystal structures were used due
to bias in the existing β1AR structures towards antagonist-bound
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Fig. 7 Additional thermostabilisation by M90A mutation shows β1AR-MetΔ5-M90A resonance positions and receptor dynamics characteristic of a less
active receptor. 2D 1H, 13C HMQC spectra (a) for [13C-methyl-Met] β1AR-MetΔ5 (blue, green) and β1AR-MetΔ5-M90A (red, purple) in the ligand-bound
form showing chemical shift changes with the orthosteric ligands isoprenaline (blue, red) and salbutamol (green, purple). Relative peak intensities (b) for
ligand-bound and ternary complexes are shown for β1AR-MetΔ5 (blue) and β1AR-MetΔ5-M90A (red). The colour-coded bars at the top and the right-hand
side of the peak intensity chart indicate the direction of increasing dynamics with generally less dynamic, rigid receptor states in blue, while red indicates
receptor states which are increasingly dynamic on the µs-to-ms timescale. Compared to β1AR-MetΔ5, the M90A mutant shows more restricted dynamics
in the ligand-only-bound forms, most notably for isoprenaline, indicating reduced conformational ﬂexibility in this state. 2D 1H, 13C HMQC spectra (c) of
the ternary isoprenaline/Nb6B9-bound β1AR-MetΔ5 (orange) and β1AR-MetΔ5-M90A (blue) show overall a similar spectral ﬁngerprint but with distinct
differences in the positions of M223 and M296 that are shifted towards the positions found in partial agonist-bound ternary complexes with the less
stabilised β1AR-MetΔ5, i.e., towards (AG−)
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conformations, with limited changes in the cytoplasmic region
following thermostabilisation (Supplementary Note 3; Supple-
mentary Table 9)34, 42. On nanobody binding, M2966.41 shifts
substantially towards the gauche conformation correlating with
increased ligand efﬁcacy. The gauche rotamer conformation also
increases slightly for M2235.54 (Supplementary Note 3; Supple-
mentary Fig. 14). As expected by their immediate proximity to
the bound nanobody, residues M153 (IL2) and M2836.28 also
show large shift changes.
Spectral changes between isoprenaline-bound receptor and the
corresponding ternary complex are much more dramatic than
those between apo- and isoprenaline-bound β1AR, suggesting
that the (A) state corresponds to a pre-active rather than a fully
active conformation (Supplementary Fig. 8). Notably, binding of a
nanobody to the cytoplasmic side of the receptor transmits
changes to the extracellular side of the receptor (‘outward’ effect),
while binding of a full agonist in the orthosteric ligand-binding
pocket results in changes as far as the cytoplasmic side of the
receptor (‘inward’ effect) (Figs 1, 4; Supplementary Fig. 8).
Nanobody-induced changes at the extracellular side of the ternary
complex include M108 (EL1), M1784.62 (TM4/EL2) and M190
(EL2), suggesting an allosteric coupling network linking opposite
faces of the receptor, where both the inward and outward effects
reinforce ternary complex formation. An increase in agonist
afﬁnity frequently accompanies IBP binding and the observed
conformational changes in EL1 and EL2 may be spectroscopic
evidence for further contraction of the orthosteric ligand-binding
environment26, 27, 41.
The structural ﬁngerprint of Nb6B9 ternary complex formation
was further investigated for other ligands (Supplementary Fig. 9).
Spectra show large chemical shift changes for M2235.54 and
M2966.41, characteristic of the cytoplasmic opening of the
receptor and nanobody docking, as previously observed with
isoprenaline. However, substantial shift differences in the ternary
complexes compared to isoprenaline, which correlate with ligand
efﬁcacy (Fig. 5; Supplementary Fig. 9), indicate conformational
variations among the ternary complexes relating to the speciﬁc
orthosteric ligand bound. A loss in relative signal intensities
suggests increased exchange broadening at lower temperature
(Supplementary Table 6) and along with the observed upﬁeld
shifts at 293 K (Supplementary Figs. 7, 10; Supplementary Note 3)
and the ligand efﬁcacy correlation, indicates the presence of a
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Fig. 8 Model of β1AR receptor activation showing partial agonism and basal activity. a β1AR ﬂuctuates between conformations that vary in the accessibility
of their cytoplasmic side. Ligand binding determines the equilibrium position between a closed, inactive state (I) and a less occluded, activated form (A) of
the receptor and also regulates the position of a second equilibrium with the active receptor bound to Gs. Agonist binding leads to a highly dynamic (A)
state of the receptor that samples multiple active-like conformations (A′, A′′, A′′′…), which vary in their ability to interact with IBPs. Coupling to Gs via
these states leads to a more, AG+, and a less active form, AG−, which are in equilibrium with each other, with their relative populations inﬂuenced by the
properties of the ligand bound. In the presence of a full agonist, both of these equilibria are shifted predominantly towards the (A) and in the presence of
Gs, AG+ states. In contrast, when bound to inactivating ligands, or in the apo form, the receptor predominantly populates the (I) state. In the apo form, small
populations of the (A) state in the presence of Gs can lead to the formation of the less active AG− state, consistent with basal activity at a low level. The
basal activity form is subsequently able to bind a ligand (grey arrow), which can lead to a further shift of the active equilibrium towards the AG+ state.
While our in vitro data show the formation of the ternary complexes via this route (grey arrow) (Supplementary Fig. 12), the physiological signiﬁcance of
this pathway is unclear and the main contribution towards ternary complex formation is likely to occur via initial binding of a ligand, followed by IBP docking
(arrows in black). b The more and less active forms of the coupled receptor show conformational differences on TM5 and TM6 that modulate their ability
to interact with GS. This could provide a mechanism to regulate signalling via the receptor’s GEF function affecting the rate of GDP release. In the presence
of partial agonists, a shift in equilibrium in the direction of AG− results in reduced levels of receptor signalling and lower efﬁcacy
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two-state equilibrium for ternary complexes in fast exchange on
the NMR timescale at 308 K (Supplementary Table 3).
Two mechanisms have been proposed to explain ligand-
dependent efﬁcacy: partial agonists may cause a distinct ternary
complex structural state, with reduced activity compared to the
full agonist43; alternatively, ligand efﬁcacy may modulate an
equilibrium between inactive and fully active ternary forms of the
receptor44. Our observations suggest that ligand efﬁcacy mod-
ulates both the equilibrium between inactive and pre-activated
states, and the conformational equilibrium between a fully acti-
vated receptor ternary complex (AG+) and a less active ternary
state (AG−), AG−⇌AG+ (Fig. 8). The two states likely differ in the
ability of the cytoplasmic region to interact with IBPs, resulting in
a variable response. As ligand efﬁcacy increases, the receptor
samples more of the fully activated (AG+) form, with adrenaline
the most active ligand in our study. This is similar to the A2AR;
however, no structural changes are observed between the pre-
active state and the ternary complex possibly due to the use of a
Gαs C-terminal peptide fragment or because A2AR adopts an
almost fully active state in the absence of IBP19. As the study uses
only one reporter (V229C6.31), structural changes distant from
this site remain undetected. Ligand efﬁcacy correlations are
observed across the cytoplasmic and extracellular halves of β1AR,
indicating that the AG−⇌AG+ equilibrium correlates with global
changes in the receptor conformation (Fig. 5), which are in fast
exchange on the NMR timescale (Supplementary Table 3).
Relative signal intensities for M2235.54 and M2966.41 show that all
ternary complexes are more rigid than the other receptor states in
this study, consistent with receptor stabilisation on coupling to an
IBP. The cyanopindolol-bound ternary complex remains slightly
more mobile (~80% maximum intensity for M2235.54), consistent
with its lower efﬁcacy as it preferentially samples the less-active
AG− state (Fig. 2; Supplementary Figs. 4, 6). In all ternary com-
plexes, M2966.41 shows more exchange broadening than
M2235.54, indicating residual TM6 motion (Supplementary
Fig. 4).
βAR are reported to show basal activity when bound to IBPs5.
For the apo state, we measured nanobody afﬁnity in the μM
range, substantially reduced from the nM afﬁnity observed in
ternary complexes38, 41. Adding an excess of nanobody demon-
strated that nanobody-bound ligand-free receptor spectra have
strong similarities to ternary nanobody complexes, consistent
with an active state (Fig. 6; Supplementary Fig. 11).
Spectral differences between the basal form and the ternary
complexes are small compared to the (unliganded) apo form, and
together with the lack of substantial changes in the cytoplasmic
residues M153 (IL2) and M2836.28 suggest that the main struc-
tural changes in TM6 and the cytoplasmic region occur on
nanobody binding (Supplementary Fig. 11). This is endorsed by
the normalised signal intensities of M2235.54 and M2966.41, which
show more restricted dynamics for the basal β1AR–nanobody
complexes, closer to the ternary complexes than the apo receptor
(Fig. 2). It also suggests that ligand binding causes further tigh-
tening of the receptor on ternary complex formation.
Isoprenaline addition to the preformed nanobody-bound
ligand-free receptor results in identical spectra to the ternary
complex formed upon nanobody addition to the isoprenaline-
bound receptor (Supplementary Fig. 12). Similar observations are
made for the other agonists (cyanopindolol, salbutamol and
adrenaline) indicating that the ﬁnal conformation of the ternary
complex is independent of the binding order.
Nanobody complex formation and spectral similarities between
the basal state and the ternary complexes suggest that sampling of
the pre-activated (A) state by the apo form of β1AR without an
agonist20, 22 can allow weak coupling to G-protein with the
potential for downstream signalling, providing an explanation for
the basal activity. M2235.54 and M2966.41 chemical shifts in the
basal state correlate with the lowest-efﬁcacy level for nanobody-
bound complexes investigated (Fig. 5), suggesting that the basal
state corresponds to the minimally activated (AG−) complex in
the AG−⇌AG+ equilibrium. Given the existence of ligand-free
basal-state GPCR-G protein complexes, and the ﬂexibility of the
(A) state, receptor selectivity for intracellular signalling pathways
may, in part, be inﬂuenced by which IBPs are expressed and
present at the cell membrane in different cell types, potentially
explaining the ability of a given ligand to activate multiple sig-
nalling pathways.
Spectra for the thermostabilising M90A mutant (β1AR-MetΔ5-
M90A)39 in the apo state are hardly changed from β1AR-MetΔ5
(Supplementary Fig. 13), indicating that in the absence of a
ligand, the thermostabilising mutation has little effect. The shift of
M2235.54 and M2966.41 signals in ligand-bound spectra of β1AR-
MetΔ5-M90A towards those from β1AR-MetΔ5 when bound to
lower-efﬁcacy ligands, both in the absence and presence of Nb6B9
(Fig. 7a, c), implies that the thermostabilising mutation reduces
receptor activity. Temperature-dependent chemical shift changes
of similar size and sign to β1AR-MetΔ5 are still observed for
M2235.54 and M2966.41, emphasising that the fast-exchanging
equilibria, I⇌A and AG−⇌AG+, still exist, albeit shifted towards
the less active state for each equilibrium (Supplementary Fig. 7).
Relative peak intensities show dramatically reduced μs-to-ms
dynamics for isoprenaline- and salbutamol-bound β1AR-MetΔ5-
M90A, consistent with a shift in the equilibria, revealing sub-
stantially more rigid agonist-bound receptor (Fig. 7a, b), while the
dynamics of the apo form is hardly affected. The relative signal
intensities do not show any temperature or ﬁeld dependence,
indicating reduced sampling of the (A) state via a left-shift in the
I⇌A equilibrium (Supplementary Table 7). Based on our data, it
is currently not clear if stabilisation also changes the dynamics of
the (A) state, which might change the sampling of the active-like
(A′, A′′, A′′′…) conformations leading to sharpening of the
M2235.54 and M2966.41 signals or if the (A) state is just less
populated. As the receptor retains its ability to form ternary
complexes, it can be assumed that such states are being sampled.
The ternary complexes show no change in dynamics compared to
β1AR-MetΔ5. Overall, thermostabilisation is similar to reducing
the efﬁcacy of a particular ligand, shifting ligand-bound and
ternary complex equilibria towards the less active state.
Using NMR spectroscopy, we investigated the conformational
diversity and dynamic nature of β1AR activation through
orthosteric ligands and Gs-mimetic nanobodies. We provide
structural insight into partial agonism and basal activity, pre-
senting our conclusions as a model (Fig. 8). The receptor popu-
lates two ligand efﬁcacy-dependent equilibria, between an inactive
(I) and pre-activated (A) form and, for the receptor bound to Gs-
mimetic, between more (AG+) and less (AG−) active forms of the
nanobody-bound receptor. The less active IBP-bound form is
consistent with the conformation of the basal activity complex.
Full agonist binding results in a highly dynamic pre-activated
form that samples multiple active-like conformations, competent
to bind IBPs. Two different conformations can be distinguished at
lower temperature with additional broadened or low-populated
states possibly remaining undetected. We suggest that the dif-
ferent states enable preferential interaction with particular IBPs
with the relative populations of these states modulated by dif-
ferent ligands. Bound to a Gs-mimetic, the receptor becomes less
mobile with allosteric modulation of the cytoplasmic interaction
by the ligand in the orthosteric binding pocket. According to our
data, orthosteric ligand efﬁcacy is converted into a distinct con-
formational response on the cytoplasmic side. Differences
between the (AG−) and (AG+) states occur on TM5 and TM6,
indicating that these conformational variations may modulate the
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receptor–nanobody interaction. We speculate that when β1AR is
bound to Gαs, these differences may contribute to conformational
changes regulating the rate of GDP release, providing control of
the GEF function of the GPCR. Through this mechanism, ligands
may modulate the efﬁcacy of downstream signalling by the
receptor.
Methods
Constructs and mutagenesis. The β1AR-Met2 construct used here was derived
from the truncated turkey β1AR receptor β44-m2334; through the reversal of three
stabilising mutations (V90M2.53, A227Y5.58 and L282A (IL3)), and the inclusion of
two further mutations (E130W3.41 and D322K7.32). To reduce spectral overlap, ﬁve
methionine residues were mutated (M44L1.35, M48L1.57, M179L (EL2), M281A
(IL3), M338A7.48) along with a further reversal of the stabilising mutation
(K322D7.32), creating the construct Met2-Δ5. Therefore, Met2-Δ5 differs from the
wild-type receptor in the truncation of the N- and C-termini, and of intracellular
loop 3 (IL3), in addition to the presence of four thermostabilising point mutations,
the mutation of ﬁve methionine residues as well as the presence of a mutation
increasing expression yield (C116L3.27) and the removal of a palmitoylation site
(C358A). For ease of puriﬁcation, a C-terminal octahistidine tag was added. The
sequence of Met2-Δ5 is.
MGAELLSQQWEA GLSLLLALVVLLI VAGNVLVIAAIGSTQRLQTLTNLFIT
SLACADLVMGLLVVPFGA TLVVRGTWL WGSFLCELWTSL DVLCVTASIWT
LCVIAIDRYLAITS PFRYQSLM TRARAKVIICTVW AISALVSFLPIMLHWWR
DEDPQALKCYQDP GCCDFVTN RAYAIASSIISFYIPL LIMIFVYLRVYREAKE
QIRKIDRASKR KTSRVAAMREH KALKTLGIIMGVFT LCWLPFFLVNIVNVFN
RDLVPDWLFVAFNWLGY ANSAANP IIYCRSPDF RKAFKRLLAFPRKAD
RRLHHHH HHHH.
For assignment purposes, methionine residues were substituted using site-
directed mutagenesis in a PCR reaction (primer sequences given in Supplementary
Table 10) using Phusion DNA polymerase (ThermoFisher). DpnI-digested PCR
product was transformed into DH5α Escherichia coli cells (New England Biolabs)
along with the transfer plasmid, and the resulting plasmid DNA construct was
isolated using a commercial Miniprep kit (Qiagen) ready for transfection in insect
cells.
Expression and puriﬁcation of β1AR. Baculovirus was generated for expression
using FlashBac viral DNA (Oxford Expression Technologies). β1AR containing
pBacPAK8 plasmid was diluted to 100 ng µL−1 and 1.8 µL, together with 1.8 µl of
FlashBac DNA, was added to 1.8 µL of previously dissolved and NaOH-neutralised
polyethylenimine (linear PEI 25000, Polysciences, 1 mgmL−1 concentration) and
diluted with 360 µL of cell culture media (SF4, Bioconcept). The mixture was
incubated at room temperature for 45 min to allow for DNA–polymer complexes
to form. The complex mixture was added to 1 mL of mid-log phase Sf9 cells
(ThermoFisher), diluted to 0.5 × 106 cells mL−1 in serum-free SF4 media and
incubated at 27 °C shaking for 5 days. On day 5, a small sample was taken to
conﬁrm visual signs of infection. The resulting P0 viral stock was diluted to 4 mL
with fresh media and incubated for 48 h to generate P1 viral stock. An aliquot of
100 µL of P1 stock was used to infect 50 mL of cells at a density of 1 × 106 cells mL
−1, and incubated at 27 °C shaking for 48 h, generating a high-titre P2 stock for
protein expression45.
For β1AR expression, Sf9 or Sf21 cells (ThermoFisher), grown in serum-free SF4
media were centrifuged (500×g, 10 min) and washed with sterile PBS, to reduce the
carry-over of unlabelled methionine. The washed cells were diluted to a density of
3 × 106 cells mL−1 into methionine-deﬁcient SF4 media at half the intended ﬁnal
culture volume. The culture was then infected with 4 mL L−1 of high-density viral
stock, and incubated for 5 h, before supplementing the culture with 250 mg L−1 of
13C methyl methionine and diluting to a ﬁnal density of 1.5 × 106 cells mL−1. The
initial reduction in culture volume ensures optimal aeration in the initial phase of
the viral infection. Cells were grown at 27 °C for 48 h and were harvested by
centrifugation (3500×g, 15 min).
The frozen insect cell pellet was thawed with solubilisation buffer (20 mM Tris-
HCl, pH 8.0, 350 mM NaCl, 3 mM imidazole, Complete Protease Inhbitor Cocktail
(Roche) and 2% LMNG) and stirred for 1 h. The solubilised cells were clariﬁed by
centrifugation (175,000×g, 45 min) and the soluble fraction was loaded onto a
nickel afﬁnity column. The column was washed with equilibration buffer (20 mM
Tris-HCl, pH 8.0, 350 mM NaCl, 3 mM imidazole and 0.02% LMNG) and the
protein was eluted with the same buffer supplemented with 250 mM imidazole.
The ﬁnal sample was exchanged into 10 mM Tris-HCl, pH 8.0, 150 mM NaCl and
0.04% LMNG.
E. coli expression and puriﬁcation of Nb80 and Nb6B9. Nb80- and Nb6b9-
containing plasmids were transformed into BL21(DE3) (New England Biolabs)
cells and grown in LB media supplemented with the relevant antibiotics. Expres-
sion cultures were inoculated with a saturated overnight culture to an OD600
density of 0.1 AU and grown to a density of 0.8 AU at 37 °C. Induction was
achieved with isopropyl thiogalactopyranoside (IPTG) at a ﬁnal concentration of
0.5 mM. Expression cultures were grown at 25 °C for 16 h before harvesting by
centrifugation (3500×g, 20 min, 4 °C).
Frozen cell pellets were thawed in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl with
Complete Protease Inhibitor Cocktail (Roche) and lysed with an EmulsiFlex C5
homogeniser (Avestin). The solubilised cells were clariﬁed by centrifugation
(175,000×g, 15 min) and the soluble fraction was loaded onto a nickel afﬁnity
column. Unbound sample was removed with wash buffer (20 mM Tris-HCl, pH
8.0, 150 mM NaCl), followed by a further wash of the same composition
supplemented with 6 mM imidazole. Nanobodies were eluted with wash buffer
containing 250 mM imidazole. A further size-exclusion chromatography step on a
Superdex S200 10/300 Increase column yielded a 95% pure protein preparation in
20 mM Tris-HCl, pH 8.0, 150 mM NaCl. Typical yields of Nb80 and Nb6b9
obtained by this method were 25 and 4 mg L−1, respectively.
NMR experiments. NMR samples were prepared with 5% D2O and the ligand was
added directly to the receptor in the apo form. The ﬁnal ligand concentrations were
1 mM salbutamol, isoprenaline, adrenaline, 200 µM carvedilol, 140 µM or 600 µM S
(−)-cyanopindolol and 100 µM 7-methylcyanopindolol. Ligand-bound populations
were all > 99.9% (Supplementary Table 11). Nanobody was added in a molar excess
for ternary complex formation and in 15-fold excess for basal complex formation.
NMR experiments were recorded on a Bruker Avance AVIII 800 spectrometer (1H
800MHz) equipped with a 5-mm TXI HCN/z cryoprobe or where speciﬁed on a
Bruker Avance AVIII 600 spectrometer (1H 600MHz) equipped with a 5-mm QCI
HCNF/z cryoprobe.
Unless speciﬁcally mentioned experiments were acquired at 308 K using a
SOFAST 1H, 13C HMQC experiment46 with gradient coherence-order selection47
and non-uniform sampling (NUS) in the 13C dimension. Gradient selection was
required to reduce the intense LMNG detergent signals, while selective excitation of
methyl groups enabled use of a short recycle delay of 0.5 s. Excitation used a 2.25-
ms 120° PC9 pulse48 and inversion a 1.16-ms, 180° REBURP pulse49. A 60%
Poisson-gap sampling schedule was used (60 complex points from a total of 100
complex points)50, with a maximum acquisition time (tmax) of 25 ms and spectral
width (13C) of 4000 Hz. The direct (1H) dimension was acquired with 10,000 Hz
spectral width, 1024 points and tmax = 51.2 ms. Spectra were recorded with
368 scans, giving an acquisition time of ~6 h. Where higher sensitivity was
required, multiple 6 h experiments were recorded and added. Spectra were
reconstructed using the iterative hard thresholding (IHT) compressed sensing (CS)
implementation51 in the Cambridge CS package (M.J. Bostock, unpublished). Data
were analysed using CCPN Analysis v252.
Data availability. The authors declare that relevant data supporting the ﬁndings of
this study are available within the article and its Supplementary Information ﬁles or
on reasonable request from the corresponding author. NMR shifts are available at
the BioMagResBank (accession numbers 27292–27297).
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